Description
Description: Cyramza (ramucirumab) is a monoclonal antibody that acts as a vascular endothelial growth factor receptor 2 (VEGFR2) antagonist, used in the treatment of various cancers.
Contents: Each 50ml vial contains 500mg of ramucirumab.
Uses:
- Gastric Cancer: As a single agent or in combination with paclitaxel for advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma after prior chemotherapy.
- Non-Small Cell Lung Cancer (NSCLC): In combination with erlotinib for first-line treatment of metastatic NSCLC with specific genetic mutations, or with docetaxel for patients with disease progression after platinum-based chemotherapy.
- Colorectal Cancer: In combination with FOLFIRI for metastatic colorectal cancer after prior therapy.
- Hepatocellular Carcinoma: As a single agent for patients with hepatocellular carcinoma who have an alpha-fetoprotein level of ≥400 ng/mL.
How it Works: Ramucirumab binds to VEGFR2, inhibiting the interaction between VEGF and its receptor, which reduces blood supply to tumors and slows their growth.
Directions for Use: Administered via intravenous infusion. The recommended dose is typically 8 mg/kg every 2 weeks. Infusion should be performed over 60 minutes, and it should not be given as an intravenous push or bolus.
Side Effects:
- Common side effects include hypertension, fatigue, diarrhea, nausea, and decreased appetite.
- Serious side effects may include severe bleeding, gastrointestinal perforations, and arterial thromboembolic events.
Precautions:
- Monitor blood pressure regularly; manage hypertension before treatment.
- Discontinue use if severe bleeding occurs.
- Not recommended during pregnancy or breastfeeding due to potential harm to the fetus or infant.
- Patients should use effective contraception during treatment and for at least three months afterward due to potential effects on fertility.
There are no reviews yet.